Viking Therapeutics (VKTX) Misses Q1 EPS by 2c

Viking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.19), $0.02 worse than the analyst estimate of ($0.17).

Highlights from the Quarter Ended March 31, 2021:

"During the first quarter of 2021, we continued to build on the significant progress made during 2020 with both of our thyroid hormone beta receptor agonist programs," stated Brian Lian, Ph.D., chief executive officer of Viking. "We continue to enroll patients in our 52-week Phase 2b VOYAGE trial evaluating VK2809 in NASH and fibrosis, and expect to complete enrollment in the second half of 2021. With respect to our second thyroid hormone beta receptor agonist program, VK0214, we are nearing completion of a Phase 1 single ascending and multiple ascending dose study in healthy volunteers. Pending the results, we expect to initiate a Phase 1b study of VK0214 in X-ALD patients this summer. On the corporate side, our balance sheet remains solid, and we ended the first quarter with approximately $242 million in cash, providing ample runway to achieve important milestones with each of our clinical programs."

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Comfort Systems USA names new COO and Chief Strategy Officer
• Sun Communities names Ileana McAlary as general counsel and EVP